|
|
|
| Preparation of Novel Recombinant PACAP Derivative MPL-2 and Its Effect on Anti-type 2 Diabetes Mellitus |
| WANG De-hua1, MA Yi1, HAN Lei1, XIAO Xing1, LI Yan-wei1, DANG Shi-ying1, FAN Zhi-yong2, WEN Tao1, HONG An1 |
1. Department of Cell Biology of Jinan University, Institute of Biological Medicine of Jinan University, Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Guangzhou 510632, China;
2. The Second Affiliated Hospital of Guangzhou University of Chinese Medicine(Guangdong Provincial Hospital of Traditional Chinese Medicine), Guangzhou 510405, China |
|
|
|
Abstract MPL-2, a pituitary adenylate cyclase-activating polypeptide (PACAP) derivative was prepared by gene recombination engineering technique and the effect of anti-type 2 diabetes mellitus was studied in db/db mice. The results showed that the molecular weight of MPL-2 was 3 902Da, and the purity was about 97% with its yeid up to 29.3mg/(per liter of fermentation product). The in vivo glucose tolerance test on db/db mice showed that MPL-2 can effectively promote the secretion of insulin in the first phase (5-15min), and improve glucose tolerance in mice significantly. Furthermore, chronic administration of MPL-2 by daily injection for 8 weeks significantly improves lipid profiles and also greatly increases insulin sensitivity in db/db mice,which decreased the blood glucose of the mice to 63.52% of the initial value at 60min in the insulin tolerance test. At the meanwhile, the body weight, fasting blood glucose, food and water intake of db/db mice were also decreased by MPL-2, which was respectively lower 21.98%, 21.46%, 22.20% and 60.07% than that of NS group. It showed that MPL-2 was more effective than BAY55-9837. In conclusion, the recombinant MPL-2 could effectively improve the glucose tolerance, insulin sensitivity and lipid level of db/db mice, and significantly decreased body weight, fasting blood glucose, food intake and water consumption, thus play a important role in the biological treatment of type 2 diabetes. Experimental basis for the research and development of MPL-2 can also be provided.
|
|
Received: 03 January 2017
Published: 25 May 2017
|
|
|
|
Cite this article:
WANG De-hua, MA Yi, HAN Lei, XIAO Xing, LI Yan-wei, DANG Shi-ying, FAN Zhi-yong, WEN Tao, HONG An. Preparation of Novel Recombinant PACAP Derivative MPL-2 and Its Effect on Anti-type 2 Diabetes Mellitus. China Biotechnology, 2017, 37(5): 59-65.
URL:
https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170508 OR https://manu60.magtech.com.cn/biotech/Y2017/V37/I5/59
|
|
|
| [1] Miyata A, Arimura A, Dahl R R,et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochemical and Biophysical Research Communications, 1989, 164(1):567-574.
[2] Ma Y, Luo T, Xu W, et al. A new recombinant pituitary adenylate cyclase-activating peptide-derived peptide efficiently promotes glucose uptake and glucose-dependent insulin secretion. Acta Biochimica et Biophysica Sinica. 2012, 44(11):948-956.
[3] Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors:20 years after the discovery. Pharmacological Reviews. 2009, 61(3):283-357.
[4] Pan C Q, Li F, Tom I, et al. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. Journal of Pharmacology and Experimental Therapeutics. 2007, 320(2):900-906.
[5] Yu R J, Xie Q L, Dai Y, et al. Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2. Peptides, 2006. 27(6):1359-1366.
[6] Sakurai Y, Shintani N, Hayata A, et al. Trophic effects of PACAP on pancreatic islets:a mini-review. Journal of Molecular Neuroscience, 2011, 43(1):3-7.
[7] Tang C, Ahmed K, Gille A, et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nature Medicine, 2015, 21(2):173-177.
[8] Association A D. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2012, 35(Supplement 1):S64-S71.
[9] Gray S L, Cummings K J, Jirik F R, et al. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Molecular Endocrinology, 2001, 15(10):1739-1747.
[10] Nakata M, Kohno D, Shintani N, et al. PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus. Neuroscience Letters, 2004, 370(2):252-256.
[11] Tomimoto S, Ojika T, Shintani N, et al. Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice. Journal of Pharmacological Sciences, 2008, 107(1):41-48.
[12] Green B D, Irwin N, Flatt P R. Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides, 2007, 28(5):981-987.
[13] Yada T,Sakurada M, Filipsson K, et al. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. Annals of the New York Academy of Sciences, 2000, 921(1):259-263.
[14] Akesson L, Ahrén B, Manganiello V C, et al. Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. Endocrinology, 2003, 144(12):5293-5299.
[15] Åkesson L, Ahrén B, Edgren G, et al. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology, 2005, 146(2):744-750.
[16] Elghazi L, Balcazar N, Bernal-Mizrachi E. Emerging role of protein kinase B/Akt signaling in pancreatic β-cell mass and function. The international journal of biochemistry & cell biology, 2006, 38(2):157-163.
[17] Prentki M, Matschinsky F M. Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiological Reviews, 1987, 67(4):1185-1248. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
